Laboratory Denial Management in 2027: How Better Data, Prior Authorization and LIS Integration Can Protect Revenue

Every laboratory has denials.

The more useful question is why your laboratory keeps having the same ones.

Denial management has traditionally focused on what happens after a payer rejects or denies a claim.

Someone researches the account. Someone determines what went wrong. The claim is corrected, appealed or resubmitted. Then the laboratory waits for payment again.

That process may recover revenue, but it does not necessarily improve the underlying laboratory revenue cycle.

As laboratories prepare for 2027, a more useful strategy is to turn denial information into prevention intelligence.

For clinical laboratories, pathology groups, molecular diagnostics laboratories, genetics laboratories, toxicology laboratories and NGS operations, that means looking closely at front end information, prior authorization, eligibility, LIS billing integration and revenue cycle analytics.

The objective is not simply to work denials faster.

The objective is to understand why they happened and reduce the number of preventable problems that reach the payer.

What Is Laboratory Denial Management?

Laboratory denial management is the process of identifying, analyzing, correcting and reducing denied laboratory claims.

A strong denial management strategy goes further than claim rework.

It examines why denials occur, where the underlying problem entered the workflow and whether similar denials can be prevented in the future.

That distinction matters.

If a laboratory repeatedly corrects the same authorization, eligibility, documentation or data problem, the billing team may become very efficient at rework without actually improving the revenue cycle.

The more valuable question is whether the problem can be identified earlier.

Laboratory Denial Management Should Start Before the Denial

A denial is often the final result of something that happened much earlier in the revenue cycle.

• Insurance information may be inaccurate.
• Eligibility may not have been confirmed.
• An authorization requirement may not have been identified.
• Documentation may be incomplete.
• A payer specific requirement may not have been addressed.
• Information may not have transferred correctly between the LIS and billing platform.

By the time the payer responds, the laboratory may already have performed the testing and incurred the cost.

That is why modern laboratory denial management should begin before claim submission whenever practical.

The objective is to identify preventable problems while the laboratory still has an opportunity to address them.

Turn Denial Codes Into Business Intelligence

A denial report should tell leadership more than how many claims were denied.

It should help explain why.

Laboratories should be able to examine denial patterns by payer, reason, test, location or other meaningful variables.

If one payer repeatedly denies claims because of authorization, that is not simply a collections issue. It may indicate a front end workflow issue.

If another payer repeatedly rejects claims because information is missing, the laboratory should determine where that information should have entered the process.

If a particular test generates a disproportionate number of denials, leadership should be able to see that pattern.

When denial information is analyzed this way, billing becomes more than transaction processing.

It becomes operational intelligence.

Prior Authorization and Eligibility Need to Move Upstream

Prior authorization and eligibility can be important components of laboratory denial prevention.

Eligibility verification can help determine whether coverage is active and whether patient and insurance information is accurate.

Prior authorization workflows can help identify tests or payer plans that may require additional action.

Neither process guarantees reimbursement.

They can, however, help identify potential problems earlier.

Timing matters.

Finding an authorization issue before testing or claim submission can provide more options than discovering it after a denial.

Laboratories should therefore consider how payer requirements are identified and communicated across the revenue cycle.

The goal is to give staff useful information at the point where action can still be taken.

Why LIS Billing Integration Matters

A laboratory's LIS or LIMS contains information the revenue cycle depends on.

The billing platform contains information laboratory leadership needs in order to understand whether testing is becoming revenue.

Those systems should communicate efficiently.

When they do not, staff members often compensate manually.

They reenter information. They search for missing data. They reconcile records. They move between systems. They build spreadsheets to fill information gaps.

Every additional manual step creates work and introduces another opportunity for error.

LIS billing integration can help create a more consistent flow of information between laboratory operations and financial workflows.

ADS and ADSRCM support integration with virtually any LIS or LIMS, as well as integrations with other systems when needed.

The goal is to reduce unnecessary administrative friction while helping the billing operation receive the information it needs.

Related Resource: Explore ADS laboratory billing software and RCM

Pathology Billing Adds Another Layer of Complexity

Pathology billing can involve additional operational considerations because information may need to move among the laboratory, ordering provider, pathologist, billing operation and payer.

Depending on the service and organizational structure, professional and technical components may need to be handled appropriately.

• Documentation needs to support the service.
• Coding needs to accurately reflect what was performed.
• Payer requirements need to be understood.
• Claims need to be tracked through payment.

A disconnected workflow makes those responsibilities harder.

That is why pathology billing technology should provide more than claim submission.

Pathology laboratories and groups need visibility into claim status, denials, accounts receivable, payer performance and reimbursement trends.

They also need effective integration between laboratory operations and billing.

Laboratory RCM Is Becoming a Data Strategy

Revenue cycle management has often been viewed primarily as a collections function.

That definition is increasingly incomplete.

Modern laboratory RCM produces information about financial interactions between the laboratory and its payers.

• Which payer is slowing down?
• Which tests generate the most denials?
• Where is A/R accumulating?
• How long does reimbursement take?
• Are certain workflows creating more billing problems?
• How much revenue is sitting beyond 90 or 120 days?
• What percentage of claims requires manual intervention?

Those answers can influence staffing, payer discussions, technology decisions and growth strategy.

Laboratory revenue cycle information should therefore be useful outside the billing department.

It should help leadership run the business.

Why Financial Visibility Matters Going Into 2027

Medicare laboratory reimbursement is another reason laboratories should understand their financial baseline.

The 2026 PAMA data reporting period ended July 31, 2026.

CMS states that the information reported during the 2026 reporting period is part of the process used to establish Clinical Laboratory Fee Schedule payment rates for 2027 through 2029.

There is no PAMA phase in reduction for 2026.

Beginning in 2027, applicable payment reductions resulting from implementation of private payer data may be subject to an annual reduction cap of 15 percent compared with the preceding year's payment amount through 2029.

That does not mean every laboratory or every test will experience the same change.

It does mean that preventable revenue leakage deserves attention when reimbursement conditions are changing.

• A claim that should have been paid but was not matters.
• A recurring denial matters.
• An authorization problem matters.
• An A/R balance that is not being worked matters.

Revenue cycle efficiency becomes increasingly important when laboratories are operating in a changing reimbursement environment.

Related Resource: laboratory billing and RCM trends for 2027

In House Laboratory Billing or Outsourced RCM?

Another question worth asking before 2027 is whether the current billing model still makes sense.

Keeping billing in house can provide control and institutional knowledge.

It also requires recruiting, training, management, technology and specialized expertise.

Outsourced laboratory RCM can provide access to specialized billing resources and reduce some administrative responsibility.

Transparency remains important regardless of the model.

Laboratory leadership should still understand performance, denials, collections and A/R.

ADS supports both approaches.

Laboratories can use ADS billing technology with their internal billing team or work with ADSRCM for outsourced laboratory revenue cycle management.

That means the conversation can start with the laboratory's needs rather than a predetermined service model.

What Should a Laboratory Revenue Cycle Dashboard Show?

A dashboard should answer questions, not simply display charts.

Laboratory executives should be able to quickly understand claim acceptance performance, denial trends, denial reasons, days in A/R, A/R aging, collections, payer performance, revenue trends, billing productivity and outstanding balances.

The exact KPIs will vary by laboratory.

The important point is accessibility.

Leadership should not have to wait until month end for someone to manually assemble several spreadsheets before understanding what happened.

ADS provides financial and operational reporting, analytics and dashboards designed to give organizations greater visibility into revenue cycle performance.

A Practical Q4 Laboratory Denial Audit

Before the end of 2026, pull denial information from the last several months.

Do not start only by asking how much money was denied.

Start by asking why.

Identify the most common denial categories.

Then determine where each problem originated.

• Was it registration?
• Eligibility?
• Authorization?
• Documentation?
• Coding?
• Payer requirements?
• Data transfer?
• Claim submission?
• Follow up?

Next, determine which problems could potentially have been detected earlier.

That exercise can reveal important information about the health of the laboratory revenue cycle.

It can also help leadership prioritize what should be fixed first.

Molecular, Genetic and NGS Billing Connects Directly to Denial Prevention

Advanced molecular testing adds another reason to move denial prevention upstream.

Molecular diagnostics billing, NGS billing and genetic testing billing can involve payer specific requirements, prior authorization, medical necessity, documentation and complex reimbursement workflows.

Laboratories performing advanced testing should understand where those requirements intersect with their revenue cycle.

Related Resource: Molecular Diagnostics, NGS and Genetic Testing Billing in 2027

Frequently Asked Questions About Laboratory Denial Management

What is laboratory denial management?

Laboratory denial management is the process of identifying, analyzing, correcting and reducing denied laboratory claims. A strong strategy also examines recurring causes so preventable denials can be addressed earlier in the revenue cycle.

How can laboratories reduce claim denials?

Laboratories can analyze eligibility, prior authorization, patient and insurance information, documentation, coding, payer requirements, claim edits and denial trends. Repeated denial reasons can help identify workflows that may need improvement.

Why is prior authorization important for laboratory billing?

Some tests and payer plans may require prior authorization. Identifying applicable requirements earlier can help laboratories address potential reimbursement issues before they become downstream billing problems.

What is LIS billing integration?

LIS billing integration connects information from a laboratory information system with billing or revenue cycle workflows so necessary data can move more efficiently between laboratory operations and financial processes.

Can ADS integrate with an existing LIS or LIMS?

ADS and ADSRCM support integration with virtually any LIS or LIMS. Integrations with other healthcare systems may also be available depending on the laboratory's environment.

What is pathology billing?

Pathology billing is the revenue cycle process associated with pathology services. It can involve documentation, coding, payer requirements, claim submission, professional and technical billing considerations, payment posting, denials and A/R follow up.

What laboratory billing KPIs should executives monitor?

Useful metrics can include claim acceptance performance, denial rate and reasons, days in A/R, aging A/R, collections, payer performance, reimbursement trends and outstanding balances. The most useful KPIs depend on the laboratory's business model and goals.

Should laboratories outsource denial management or RCM?

The answer depends on staffing, expertise, technology, test mix, payer mix and financial objectives. Some laboratories benefit from maintaining billing internally with stronger technology. Others may benefit from outsourced laboratory RCM. ADS supports both models.

Make Your Denial Data Work for You

Denials are frustrating.

They are also information.

Every denial can tell a laboratory something about its workflow, data or relationship with a payer.

The goal should not be to become exceptionally good at fixing the same problems repeatedly.

The goal should be to learn from them.

• Better eligibility workflows.
• Better authorization visibility.
• Better LIS integration.
• Better analytics.
• Better denial prevention.
• Better financial visibility.

ADS and ADSRCM help clinical, pathology, molecular, genetics, NGS, toxicology and specialty laboratories improve billing performance through technology, automation, integrations, analytics and specialized revenue cycle expertise.